AIMS: @entity1717 ( @entity1717 ) is common in small-for-gestational-age (SGA) neonates. @entity6335 is often used as the first-line medication for @entity1717 in SGA neonates. Unfortunately, @entity6335 is not authorized in China. We examined the effectiveness of @entity2390 as an alternative therapy to treat @entity1717 in SGA neonates. There is limited data on the use of @entity2390 in @entity1717 of SGA neonates. METHODS: Seven SGA neonates with @entity1717 who were admitted to the Department of Neonatology at the Third Affiliated Hospital of Sun Yat-sen University between January 2013 and December 2014 received @entity2390 at an initial dose of 5  g/kg/day through subcutaneous injection at 8-hour intervals. Depending on the glycemic control, the dose of @entity2390 was increased in increments of 2-5  g/kg/day every 3-5 days to the maximum dose of 30  g/kg/day. RESULTS: The age of neonates with @entity1717 diagnosis ranged from 1 to 4 days. The maximum dose of @entity2390 ranged from 8 to 18  g/kg/day. The duration of @entity2390 therapy ranged from 9 to 45 days. All @entity1 had a clear glycemic response to @entity2390 , and no major adverse events were observed during the treatment. CONCLUSIONS: @entity2390 may be a useful alternative therapy in @entity1717 of SGA neonates when @entity6335 is unavailable.

Experience of XXXX Therapy for Hyperinsulinemic Hypoglycemia in Neonates Born Small for Gestational Age: A Case Series.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1717 :: ('MESH:D044903', 'Disease') :: ['HH', 'Hyperinsulinemic hypoglycemia'] @entity6335 :: ('MESH:D003981', 'Chemical') :: ['Diazoxide', 'diazoxide'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide', 'Octreotide']
@entity2390 :: (MESH:D015282,Chemical) :: ['Octreotide']
